Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTCSJBZ)

DTT Name	GAR transformylase (GART)
Synonyms	Phosphoribosylglycinamide formyltransferase; 5'-phosphoribosylglycinamide transformylase; GART
Gene Name	GART
DTT Type	Clinical trial target	[1]
Related Disease	Solid tumour/cancer [ICD-11: 2A00-2F9Z]
UniProt ID	PUR2_HUMAN
TTD ID	T72042
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
EC Number	EC 2.1.2.2
Sequence	VAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYK NRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHE QALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQ LVASGTVQLGENGKICWVKEE
Function	A folate-dependent enzyme, essential for the de novo purine synthesis pathway.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AG2034	DMFU58V	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DDATHF	DM6GWAC	Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------

References

1	Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7.
2	Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,... Biochemistry. 2003 May 27;42(20):6043-56.